Pascal Claudepierre
A5017486273- Spondyloarthritis Studies and Treatments
- Rheumatoid Arthritis Research and Therapies
- Psoriasis: Treatment and Pathogenesis
- Bone and Joint Diseases
- Autoimmune and Inflammatory Disorders Research
- Spine and Intervertebral Disc Pathology
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Systemic Lupus Erythematosus Research
- Therapeutic Uses of Natural Elements
- Health Systems, Economic Evaluations, Quality of Life
- Pregnancy and Medication Impact
- Healthcare Systems and Practices
- Osteoarthritis Treatment and Mechanisms
- Scoliosis diagnosis and treatment
- Infectious Diseases and Tuberculosis
- COVID-19 Clinical Research Studies
- Dermatology and Skin Diseases
- Musculoskeletal synovial abnormalities and treatments
- Musculoskeletal pain and rehabilitation
- Medical Imaging and Analysis
- Lymphoma Diagnosis and Treatment
- Clinical practice guidelines implementation
- Liver Diseases and Immunity
- Macrophage Migration Inhibitory Factor
- Tendon Structure and Treatment
Université Paris-Est Créteil
2015-2024
Centre Hospitalier Universitaire Henri-Mondor
2014-2024
Hôpitaux Universitaires Henri-Mondor
2013-2024
Assistance Publique – Hôpitaux de Paris
2015-2024
Université Gustave Eiffel
2024
Epidemiology in dermatology and evaluation of therapeutics
2020-2024
Center for Rheumatology
2024
Hôpital Albert-Chenevier
2009-2023
Société Française de Rhumatologie
2020-2022
Inserm
2017-2022
There is little known about the impact of SARS-CoV-2 on patients with inflammatory rheumatic and musculoskeletal diseases (iRMD). We examined epidemiological characteristics associated severe disease, then death. also compared mortality between hospitalised for COVID-19 without iRMD.Individuals suspected iRMD-COVID-19 were included in this French cohort. Logistic regression models adjusted age sex used to estimate ORs 95% CIs COVID-19. The most significant clinically relevant factors...
One-third of patients with rheumatoid arthritis show inadequate response to tumor necrosis factor α (TNF-α) inhibitors; little guidance on choosing the next treatment exists.To compare efficacy a non-TNF-targeted biologic (non-TNF) vs second anti-TNF drug for insufficient TNF inhibitor.A total 300 (conducted between 2009-2012) arthritis, persistent disease activity (disease score in 28 joints-erythrocyte sedimentation rate [DAS28-ESR] ≥ 3.2 [range, 0-9.3]) and an therapy were included...
Increasing number of Janus kinase (JAK) inhibitors have been approved for chronic haematopoietic neoplasms and inflammatory/autoimmune diseases. We aimed to assess safety the first three JAK inhibitors: ruxolitinib, tofacitinib baricitinib. In this retrospective observational study, pharmacovigilance data were extracted from World Health Organization database. Adverse events are classified according Medical Dictionary Regulatory Activities hierarchy. Until February 28, 2021, all Individual...
Objective. We evaluated the effectiveness and safety of adalimumab in a large cohort patients with active ankylosing spondylitis (AS) identified clinical predictors good response. Methods. Patients AS [Bath Disease Activity Index (BASDAI) ≥4] received 40 mg every other week addition to their standard antirheumatic therapies multinational 12-week, open-label study. used 3 definitions response: 50% improvement BASDAI (BASDAI = 50), 40% ASsessments SpondyloArthritis International Society...
Objective To clarify sex differences in early axial spondyloarthritis (SpA). Methods In total, 475 patients included the Devenir des Spondylarthropathies Indifférenciées Récentes (Outcome of Recent Undifferentiated Spondylarthropathies) cohort, a prospective multicenter French cohort with inflammatory back pain suggestive SpA, and fulfilling Assessment SpondyloArthritis international Society (ASAS) classification criteria for SpA were studied. The clinical imaging features compared between...
To investigate the degree of agreement between local rheumatologists/radiologists and central trained readers (external standard) on presence/absence sacroiliitis radiographs sacroiliac (SI) joints.Patients with inflammatory back pain (duration ≥3 months but <3 years) suggestive axial spondyloarthritis (SpA) were included in Devenir des Spondylarthropathies Indifferérenciées Récentes (DESIR) cohort. Baseline SI joints interpreted by 2 (modified New York criteria); cases disagreement...
To describe the prevalence of fibromyalgia (FM) in an axial spondyloarthritis (axSpA) population and to confirm that concomitant FM had a negative impact on tumour necrosis factor blockers' (TNFb) response.Prospective observational study with two visits 3 months apart.Adult patients AxSpa initiating TNFb.FM was defined by Fibromyalgia Rapid Screening Tool (FiRST) at baseline also sustained positive FiRST (both visits) fulfilment 1990 American College Rheumatology criteria for FM.Prevalence...
<h3>Importance</h3> Although tumor necrosis factor (TNF) inhibitors are widely prescribed globally because of their ability to ameliorate shared immune pathways across immune-mediated inflammatory diseases (IMIDs), the impact COVID-19 among individuals with IMIDs who receiving TNF remains insufficiently understood. <h3>Objective</h3> To examine association between receipt inhibitor monotherapy and risk COVID-19–associated hospitalization or death compared other commonly immunomodulatory...
To compare the benefits of a tight-control/treat-to-target strategy (TC/T2T) in axial spondyloarthritis (axSpA) with those usual care (UC).Pragmatic, prospective, cluster-randomised, controlled, open, 1-year trial (NCT03043846). 18 centres were randomised (1:1). Patients met Axial Spondylo Arthritis International Society (ASAS) criteria for axSpA, had an Ankylosing Spondylitis Disease Activity Score (ASDAS) ≥2.1, received non-optimal treatment by non-steroidal anti-inflammatory drugs and...
Treatment options for psoriasis (PsO) and psoriatic arthritis (PsA) have evolved significantly throughout the era of biologics. Clinical trials are inadequate to assess relative long-term efficacy biologics often insufficient regarding safety.To persistence different biologic classes treat PsO PsA.This nationwide cohort study involved administrative health care database French insurance scheme linked hospital discharge database. All adults with PsA who were new users (not in year before...
Abstract Objective Continuous treatment with the anti–tumor necrosis factor α (anti‐TNFα) antibody infliximab is efficacious in ankylosing spondylitis (AS), whereas discontinuation results disease relapse, variable delay. This study was undertaken to compare efficacy of continuous that a regimen adapted symptom recurrence. Methotrexate (MTX) combination also tested. Methods Patients active AS were randomly assigned at week 0 receive every 6 weeks (continuous treatment) or upon recurrence...
The management of spondyloarthritis is challenging and has changed with the development new concepts treatments. To develop practice guidelines for everyday patients (including psoriatic arthritis), by updating previous national international recommendations, based on a review recently published data. A task force multidisciplinary literature group were established. identified issues that remained unresolved. Based existing recommendations recent publications, developed guidelines, which...
Investigating changes in patient classification (ASAS (Assessment of SpondyloArthritis international Society) axSpA criteria) based on evaluation images the sacro-iliac joints (MRI-SI and X-SI) by local central readers.The DESIR cohort included patients with inflammatory back pain (IBP; ≥3 months, but <3 years), suggestive axSpA. Local radiologists/rheumatologists (local-reading) two readers (central-reading) evaluated baseline images. Agreement regarding positive MRI (pos-MRI) between...